Artiva Biotherapeutics Inc. (ARTV) Stock Price, Quote & News

Company Profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vascul...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 267 4467

Website: www.artivabio.com

Address:

5505 Morehouse Drive, Suite 100, San Diego, United States

LewisDaKat Jul. 17 at 2:30 PM

$ARTV Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://marketwirenews.com/stock/artv/news/artiva-biotherapeutics-announces-new-employee-induce-6819930485705014.html?utm_source=stocktwits

0 · Reply

yva Jul. 17 at 6:25 AM

$ARTV New to ARTV , never catch a falling knife? Did i? .....bought some at USD 9.22 to start....

1 · Reply

kubota2323 Jul. 15 at 10:22 PM

$ARTV Institutional Ownership Managers Funds RA CAPITAL MANAGEMENT, L.P. 39.86% 5AM Venture Management, LLC 9.52% Venrock Adviser, LLC 6.51% venBio Partners LLC 2.15% FRANKLIN RESOURCES INC 2.11% Revelation Capital Management, LLC 1.21% BlackRock, Inc. 0.86% VANGUARD CAPITAL MANAGEMENT LLC 0.84% WELLINGTON MANAGEMENT GROUP LLP 0.79% Propel Bio Management, LLC 0.59%

0 · Reply

kubota2323 Jul. 15 at 8:18 PM

$ARTV RA CAPITAL MANAGEMENT, L.P. Director May 11 '26 Buy 11.52 6,510,416 74,999,992 15,203,995 May 13 05:45 PM

0 · Reply

kubota2323 Jul. 15 at 8:16 PM

$ARTV Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4 RA CAPITAL MANAGEMENT, L.P. Director Jul 10 '26 Buy 8.97 15,102 135,465 16,811,021 Jul 14 07:00 PM RA CAPITAL MANAGEMENT, L.P. Director Jul 13 '26 Buy 8.94 6,552 58,575 16,817,573 Jul 14 07:00 PM RA CAPITAL MANAGEMENT, L.P. Director Jun 25 '26 Buy 8.88 31,000 275,280 16,794,043 Jun 29 04:20 PM RA CAPITAL MANAGEMENT, L.P. Director Jun 26 '26 Buy 8.98 1,876 16,846 16,795,919 Jun 29 04:20 PM RA CAPITAL MANAGEMENT, L.P. Director Jun 12 '26 Buy 8.57 391,019 3,351,033 16,622,736 Jun 16 06:08 PM RA CAPITAL MANAGEMENT, L.P. Director Jun 16 '26 Buy 8.89 124,893 1,110,299 16,763,043 Jun 16 06:08 PM RA CAPITAL MANAGEMENT, L.P. Director Jun 15 '26 Buy 8.99 15,414 138,572 16,638,150 Jun 16 06:08 PM RA CAPITAL MANAGEMENT, L.P. Director Jun 11 '26 Buy 7.91 548,580 4,339,268 16,231,717 Jun 11 07:36 PM RA CAPITAL MANAGEMENT, L.P. Director Jun 09 '26 Buy 6.91 479,039 3,310,159 15,683,034 Jun 11 07:36 PM

0 · Reply

kubota2323 Jul. 15 at 8:06 PM

$ARTV and still adding. Just like me

0 · Reply

Marcinoff Jul. 15 at 8:00 PM

$ARTV let's go !!! 📈

0 · Reply

AlertsAndNews Jul. 15 at 2:38 AM

$ARTV Same director bought alot more last month too. Rajeev M. Shah (Director, 10%+) purchased 21,654 shares at an average price of $8.96 (Form 4).

0 · Reply

Merlintrader Jul. 14 at 6:42 AM

$ARTV Artiva Biotherapeutics Stock Hub: $ARTV, AlloNK, FDA RMAT and the Phase 3 Rheumatoid Arthritis Path https://www.merlintrader.com/artiva-biotherapeutics-stock-hub/

0 · Reply

elmono Jul. 2 at 2:23 PM

$ARTV snail move …offering did some damage here

1 · Reply

Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2026, 3:30 PM EDT - 16 days ago

Artiva Biotherapeutics Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 23, 2026, 4:05 PM EDT - 23 days ago

Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 8, 2026, 8:15 AM EDT - 5 weeks ago

Artiva Biotherapeutics Transcript: Status update

Jun 8, 2026, 8:15 AM EDT - 5 weeks ago

Artiva Biotherapeutics Press release: Status update

2026-06-08T10:40:49.000Z - 5 weeks ago

Artiva Biotherapeutics highlights AlloNK data presented at EULAR 2026

$Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today$

Jun 8, 2026, 6:30 AM EDT - 5 weeks ago

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Jun 4, 2026, 9:20 AM EDT - 6 weeks ago

Artiva Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 8:00 AM EDT - 7 weeks ago

Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

May 19, 2026, 4:05 PM EDT - 2 months ago

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases

May 19, 2026, 8:00 AM EDT - 2 months ago

Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development

2026-05-12T18:55:13.000Z - 2 months ago

Artiva Biotherapeutics price target raised to $41 from $18 at Needham

2026-05-11T17:22:01.000Z - 2 months ago

Artiva Biotherapeutics price target raised to $40 from $23 at Wedbush

2026-05-08T20:22:09.000Z - 2 months ago

Artiva Biotherapeutics price target raised to $35 from $15 at H.C. Wainwright

May 8, 2026, 9:30 AM EDT - 2 months ago

Artiva Biotherapeutics Earnings release: Q1 2026

May 8, 2026, 9:30 AM EDT - 2 months ago

Artiva Biotherapeutics Quarterly report: Q1 2026

2026-05-08T10:59:29.000Z - 2 months ago

Artiva Biotherapeutics reports Q1 EPS (95c), consensus (84c)

May 8, 2026, 6:52 AM EDT - 2 months ago

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

2026-05-08T10:51:22.000Z - 2 months ago

Artiva reports data from clinical trials evaluating AlloNK

May 8, 2026, 6:31 AM EDT - 2 months ago

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 8, 2026, 6:30 AM EDT - 2 months ago

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Apr 15, 2026, 2:15 PM EDT - 3 months ago

Artiva Biotherapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 8:00 AM EDT - 3 months ago

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Mar 10, 2026, 4:05 PM EDT - 4 months ago

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Mar 10, 2026, 7:00 AM EDT - 4 months ago

Artiva Biotherapeutics Earnings release: Q4 2025

Mar 10, 2026, 7:00 AM EDT - 4 months ago

Artiva Biotherapeutics Annual report: Q4 2025

Mar 4, 2026, 1:10 PM EST - 4 months ago

Artiva Biotherapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:00 AM EST - 5 months ago

Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

2026-02-24T13:23:47.000Z - 5 months ago

Artiva Biotherapeutics appoints Huston as Chief Financial Officer

Feb 24, 2026, 8:00 AM EST - 5 months ago

Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

2026-02-19T13:17:45.000Z - 5 months ago

Artiva Biotherapeutics appoints Sorg to board of directors

Feb 19, 2026, 8:00 AM EST - 5 months ago

Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

Jan 21, 2026, 8:00 AM EST - 6 months ago

Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL

Nov 18, 2025, 7:00 AM EST - 8 months ago

Artiva Biotherapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 11:30 AM EST - 8 months ago

Artiva Biotherapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 8:00 AM EST - 8 months ago

Artiva Biotherapeutics Transcript: Study Update

Nov 12, 2025, 8:00 AM EST - 8 months ago

Artiva Biotherapeutics Press release: Study Update

2025-11-12T12:36:40.000Z - 8 months ago

Artiva Biotherapeutics announces safety, translational data from AlloNK

Nov 12, 2025, 7:20 AM EST - 8 months ago

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

2025-11-12T12:05:30.000Z - 8 months ago

Artiva Biotherapeutics reports Q3 EPS (88c) vs (92c) last year

Nov 12, 2025, 7:00 AM EST - 8 months ago

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:00 AM EST - 8 months ago

Artiva Biotherapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

Artiva Biotherapeutics Quarterly report: Q3 2025

Nov 3, 2025, 4:05 PM EST - 9 months ago

Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

Oct 30, 2025, 4:17 PM EDT - 9 months ago

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

2025-10-17T13:16:24.000Z - 9 months ago

Why Is Artiva Biotherapeutics Stock (ARTV) Up 105% Today?

2025-10-17T12:00:36.000Z - 9 months ago

Artiva Biotherapeutics price target raised to $23 from $18 at Wedbush

$Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update$

Oct 16, 2025, 4:05 PM EDT - 9 months ago

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Sep 3, 2025, 9:45 AM EDT - 11 months ago

Artiva Biotherapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 25, 2025, 4:05 PM EDT - 11 months ago

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

2025-08-06T21:21:24.000Z - 1 year ago

Artiva Biotherapeutics files $300M mixed securities shelf

Aug 6, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

Aug 6, 2025, 9:30 AM EDT - 1 year ago

Artiva Biotherapeutics Quarterly report: Q2 2025

Aug 6, 2025, 9:30 AM EDT - 1 year ago

Artiva Biotherapeutics Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Artiva Biotherapeutics Registration statement: Registration Filing

2025-06-11T10:21:17.000Z - 1 year ago

Artiva Biotherapeutics assumed with a Buy at H.C. Wainwright

Jun 4, 2025, 9:20 AM EDT - 1 year ago

Artiva Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

2025-05-13T21:05:16.000Z - 1 year ago

Artiva Biotherapeutics announces new, long-term data for AlloNK combination

May 13, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

2025-05-08T12:41:18.000Z - 1 year ago

Artiva Biotherapeutics reports Q1 EPS (83c) vs. ($17.24) last year

2025-05-08T12:40:47.000Z - 1 year ago

Artiva Biotherapeutics sees cash runway into 2Q27

May 8, 2025, 8:00 AM EDT - 1 year ago

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

May 8, 2025, 7:00 AM EDT - 1 year ago

Artiva Biotherapeutics Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Artiva Biotherapeutics Earnings release: Q1 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Artiva Biotherapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Artiva Biotherapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 4:35 PM EDT - 1 year ago

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Apr 8, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Apr 7, 2025, 11:00 AM EDT - 1 year ago

Artiva Biotherapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 24, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025, 9:00 AM EDT - 1 year ago

Artiva Biotherapeutics Annual report: Q4 2024

Mar 24, 2025, 9:00 AM EDT - 1 year ago

Artiva Biotherapeutics Earnings release: Q4 2024

Mar 5, 2025, 2:30 PM EST - 1 year ago

Artiva Biotherapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 20, 2025, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Jan 29, 2025, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

Nov 20, 2024, 10:30 AM EST - 1 year ago

Artiva Biotherapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 12, 2024, 4:00 PM EST - 1 year ago

Artiva Biotherapeutics Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Artiva Biotherapeutics Earnings release: Q3 2024

Nov 11, 2024, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

Oct 22, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Sep 10, 2024, 4:05 PM EDT - 2 years ago

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 29, 2024, 4:05 PM EDT - 2 years ago

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 29, 2024, 7:00 AM EDT - 2 years ago

Artiva Biotherapeutics Quarterly report: Q2 2024

Aug 29, 2024, 7:00 AM EDT - 2 years ago

Artiva Biotherapeutics Earnings release: Q2 2024

Jul 18, 2024, 7:08 PM EDT - 2 years ago

Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering

LewisDaKat Jul. 17 at 2:30 PM

0 · Reply

yva Jul. 17 at 6:25 AM

$ARTV New to ARTV , never catch a falling knife? Did i? .....bought some at USD 9.22 to start....

1 · Reply

kubota2323 Jul. 15 at 10:22 PM

0 · Reply

kubota2323 Jul. 15 at 8:18 PM

$ARTV RA CAPITAL MANAGEMENT, L.P. Director May 11 '26 Buy 11.52 6,510,416 74,999,992 15,203,995 May 13 05:45 PM

0 · Reply

kubota2323 Jul. 15 at 8:16 PM

0 · Reply

kubota2323 Jul. 15 at 8:06 PM

$ARTV and still adding. Just like me

0 · Reply

Marcinoff Jul. 15 at 8:00 PM

$ARTV let's go !!! 📈

0 · Reply

AlertsAndNews Jul. 15 at 2:38 AM

$ARTV Same director bought alot more last month too. Rajeev M. Shah (Director, 10%+) purchased 21,654 shares at an average price of $8.96 (Form 4).

0 · Reply

Merlintrader Jul. 14 at 6:42 AM

$ARTV Artiva Biotherapeutics Stock Hub: $ARTV, AlloNK, FDA RMAT and the Phase 3 Rheumatoid Arthritis Path https://www.merlintrader.com/artiva-biotherapeutics-stock-hub/

0 · Reply

elmono Jul. 2 at 2:23 PM

$ARTV snail move …offering did some damage here

1 · Reply

prismmarketview Jul. 2 at 1:55 PM

The autoimmune cell therapy wave mostly runs through autologous CAR-T, which is expensive and inpatient. #ArtivaBio (Nasdaq: $ARTV ) is trying an off-the-shelf route: AlloNK, a donor-derived NK cell therapy paired with rituximab to reset B cells in refractory rheumatoid arthritis. June's EULAR data read well and the FDA granted RMAT designation. The counts are still thin, so a funded Phase 3 is the real test. https://prismmarketview.com/artivas-off-the-shelf-answer-to-autoimmune-car-t/

0 · Reply

aletz Jun. 23 at 9:30 PM

$ARTV I'm super excited to go long here. It's got amazing potential, backed by top-notch efficacy and safety data. Plus, they have enough cash to get through Phase 3. And there's another indication coming later this year!

0 · Reply

StockDaddy68 Jun. 18 at 11:49 AM

$FATE Good Morning Everyone! I'm curious what do you folks think about $ARTV

1 · Reply

iQuicky Jun. 17 at 5:57 PM

$INDP $CVKD $ARTV $REPL $RCKT investing in their future!

0 · Reply

dougdchef Jun. 17 at 4:28 PM

$ARTV … Even COOLer

0 · Reply

Roaring_Capybara Jun. 17 at 11:23 AM

$ARTV RA Capital disclosed yesterday the acquisition of an additional 530,000 shares at market. This is on top of the 1,030,000 shares disclosed a few days ago.

1 · Reply

Roaring_Capybara Jun. 17 at 11:08 AM

$ARTV Big insider purchase always perks my interest - I'm in for 2K shares.

1 · Reply

Think_Bigly Jun. 17 at 12:59 AM

$ARTV Hey! How about giving the rest of us a shot at $8?

0 · Reply

FilingTracker Jun. 16 at 10:09 PM

$ARTV $4.6 million insider purchase: https://filingtracker.ai/filing/1817241/0001231919-26-000656

0 · Reply

Papermoon347 Jun. 16 at 5:17 AM

$ARTV Let's hope we turned to the upside anything under $11.52 is good under $10 is gold !

0 · Reply

dougdchef Jun. 15 at 1:55 PM

$ARTV … COOL

0 · Reply

stockdog88 Jun. 12 at 9:08 PM

$ARTV $NVDA $Q $SPCX how do you know the future? Please share …..

2 · Reply

Market Cap	N/A
Revenue (ttm)	33.49M
Net Income (ttm)	-27.70M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	342,500
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	Strong Buy
Price Target	N/A